A Visual Interpretation Algorithm for Assessing Brain Tauopathy with 18F-MK-6240 PET

Visual Abstract In vivo characterization of pathologic deposition of tau protein in the human brain by PET imaging is a promising tool in drug development trials of Alzheimer disease (AD). 6-(fluoro-18F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine (18F-MK-6240) is a radiotracer with high selectivity and subnanomolar affinity for neurofibrillary tangles that shows favorable nonspecific brain penetration and excellent kinetic properties. The purpose of the present investigation was to develop a visual assessment method that provides both an overall assessment of brain tauopathy and regional characterization of abnormal tau deposition. Methods: 18F-MK-6240 scans from 102 participants (including cognitively normal volunteers and patients with AD or other neurodegenerative disorders) were reviewed by an expert nuclear medicine physician masked to each participant’s diagnosis to identify common patterns of brain uptake. This initial visual read method was field-tested in a separate, nonoverlapping cohort of 102 participants, with 2 additional naïve readers trained on the method. Visual read outcomes were compared with semiquantitative assessments using volume-of-interest SUV ratio. Results: For the visual read, the readers assessed 8 gray-matter regions per hemisphere as negative (no abnormal uptake) or positive (1%–25% of the region involved, 25%–75% involvement, or >75% involvement) and then characterized the tau binding pattern as positive or negative for evidence of tau and, if positive, whether brain uptake was in an AD pattern. The readers demonstrated agreement 94% of the time for overall positivity or negativity. Concordance on the determination of regional binary outcomes (negative or positive) showed agreement of 74.3% and a Fleiss κ of 0.912. Using clinical diagnosis as the ground truth, the readers demonstrated a sensitivity of 73%–79% and specificity of 91%–93%, with a combined reader-concordance sensitivity of 80% and specificity of 93%. The average SUV ratio in cortical regions showed a robust correlation with visually derived ratings of regional involvement (r = 0.73, P < 0.0001). Conclusion: We developed a visual read algorithm for 18F-MK-6240 PET offering determination of both scan positivity and the regional degree of cortical involvement. These cross-sectional results show strong interreader concordance on both binary and regional assessments of tau deposition, as well as good sensitivity and excellent specificity supporting use as a tool for clinical trials.

[1]  G. Rabinovici,et al.  The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. , 2022, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  J. Morris,et al.  Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[3]  J. Gee,et al.  Rates of longitudinal change in 18F‐flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[4]  Julie Gonneaud,et al.  Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography. , 2020, JAMA neurology.

[5]  David T. Jones,et al.  The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes , 2019, Brain : a journal of neurology.

[6]  Sterling C. Johnson,et al.  In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls , 2018, The Journal of Nuclear Medicine.

[7]  H. Braak,et al.  Top-Down Projections Direct the Gradual Progression of Alzheimer-Related Tau Pathology Throughout the Neocortex. , 2019, Advances in experimental medicine and biology.

[8]  David T. Jones,et al.  Joint associations of β-amyloidosis and cortical thickness with cognition , 2018, Neurobiology of Aging.

[9]  Daniel R. Schonhaut,et al.  Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease , 2017, Brain : a journal of neurology.

[10]  Keith A. Johnson,et al.  Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global &bgr;-Amyloid Burden , 2017, JAMA neurology.

[11]  Yiyun Huang,et al.  PET Imaging for Early Detection of Alzheimer's Disease: From Pathologic to Physiologic Biomarkers. , 2017, PET clinics.

[12]  O. Hansson,et al.  Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks , 2017, Front. Neurosci..

[13]  Gereon R Fink,et al.  In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[14]  H. Braak,et al.  Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases. , 2016, Cold Spring Harbor perspectives in biology.

[15]  Talakad G. Lohith,et al.  Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles , 2016, The Journal of Nuclear Medicine.

[16]  A. Joshi,et al.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.

[17]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.